Artiva Biotherapeutics Doses First Patient with AlloNK in the P-I Study for Treating Lupus Nephritis
Shots:
- Artiva has dosed the first patient with AlloNK (AB-101) in P-I study assessing its safety & clinical activity combined with rituximab or obinutuzumab in patients who failed treatment for class III/IV LN. The company will partner with Lupus Therapeutics for the trial
- The company’s AlloNK was further analyzed in P-I/II combined with rituximab for r/r B-NHL that demonstrated its ability of B-cell depletion to reset the immune system in all 29 patients, supporting the MOA. CRs were also seen in patients, suggesting its efficacy to treat autoimmune diseases due to common lymphoid tissue involvement
- AlloNK, a non-genetically modified, allogeneic, cryopreserved NK cell therapy, enhances B-cell targeting mAbs, leading to B-cell depletion
Ref: Artiva Biotherapeutics | Image: Artiva Biotherapeutics
Related News:- Artiva Biotherapeutics Receives the US FDA’s Fast Track Designation for AlloNK (AB-101) to Treat Lupus Nephritis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
